WHO Approves Covaxin: The World Health Organization (WHO) granted an emergency use listing to Covaxin on Wednesday. This would mean that the Bharat Biotech’s COVID-19 vaccine made in India will now be recognised by other countries as well as India. The individuals who take the vaccine will not need to self-quarantine or face restrictions while travelling abroad.
The WHO in a tweet wrote, “WHO has granted emergency use listing (EUL) to COVAXIN (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of COVID-19.”
The manufactures at Bharat Biotech had applied for emergency listing, EUL, of the Covaxin in April this year. The approval by WHO comes after months of review. The manufacturers had submitted the required data in July. The data included information about the vaccine’s safety, stability and efficacy as well as checks of production facilities.
Due to the delay in WHO approval, many Indian students, families and working professionals had faced problems in terms of travelling outside the country. Covaxin was being accepted by other countries of the world. Technical Advisory Group, independent panel that provides recommendations to the WHO had asked for additional clarifications to conduct a ‘final risk-benefit assessment’ last week.
According to a report by PTI, Dr Margaret Harris, the spokesperson of WHO had said, “… if the committee is satisfied, we expect a recommendation within the next 24 hours or so.” WHO also said that even though many people are waiting for the vaccine to be approved it “cannot cut corners before recommending a product for emergency use… we must evaluate thoroughly to make it is safe and effective”.
According to the global health body, the timeframe within which a vaccine gets EUL depends on how quickly the manufacturers provide them with the required data.
As of November 3 over 12 crore people in India have been vaccinated either with Serum Institute’s Covishield or Covaxin. It is one of the few ‘made-in-india’ vaccines. The makers of the vaccine had stated that it gives 77.8 per cent effectiveness against the symptomatic COVID-19 and 65.2 per cent protection against the Delta variant.
Watch Trending Video Now:
We request you to support our award-winning journalism by making a financial contribution towards our efforts. Your funds will ensure we can continue to bring you amazing stories of women, and the impact they are making and spotlight half the country's population because they deserve it.